Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Depreciation & Amortization (CF) (2016 - 2025)

Apyx Medical's Depreciation & Amortization (CF) history spans 15 years, with the latest figure at $221000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 55.63% year-over-year to $221000.0; the TTM value through Dec 2025 reached $655000.0, up 9.35%, while the annual FY2025 figure was $655000.0, 9.35% up from the prior year.
  • Depreciation & Amortization (CF) reached $221000.0 in Q4 2025 per APYX's latest filing, up from $164000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $247000.0 in Q2 2022 to a low of $132000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $186950.0, with a median of $194000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 38.87% in 2023, then soared 55.63% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $229000.0 in 2021, then fell by 11.79% to $202000.0 in 2022, then dropped by 24.75% to $152000.0 in 2023, then dropped by 6.58% to $142000.0 in 2024, then skyrocketed by 55.63% to $221000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Depreciation & Amortization (CF) are $221000.0 (Q4 2025), $164000.0 (Q3 2025), and $132000.0 (Q2 2025).